Aquestive Therapeutics Inc (NASDAQ:AQST) price on Thursday, February 06, fall -2.27% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.02.
A look at the stock’s price movement, the close in the last trading session was $3.09, moving within a range at $3.01 and $3.13. The beta value (5-Year monthly) was 2.816. Turning to its 52-week performance, $6.23 and $2.24 were the 52-week high and 52-week low respectively. Overall, AQST moved -8.48% over the past month.
Aquestive Therapeutics Inc’s market cap currently stands at around $275.36 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 13.11M for the company’s revenue for the quarter, with a low and high estimate of 11.4M and 15.6M respectively. The average forecast suggests down to a -0.71% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 57.5M, representing a 13.67% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AQST is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend AQST as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AQST’s current price about -2.22% and -16.32% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.47, while 7-day volatility ratio is 4.54% and 5.25% in the 30-day chart. Further, Aquestive Therapeutics Inc (AQST) has a beta value of 2.75, and an average true range (ATR) of 0.17. Analysts have given the company’s stock an average 52-week price target of $10, forecast between a low of $10 and high of $10. Looking at the price targets, the low is -231.13% off current price level while to achieve the yearly target high, price needs to move -231.13%. Nonetheless, investors will most likely welcome a -231.13% jump to $10 which is the analysts’ median price.
If we refocus on Aquestive Therapeutics Inc (NASDAQ:AQST), historical trading data shows that trading volumes averaged 1.14 over the past 10 days and 1.50 million over the past 3 months. The company’s latest data on shares outstanding shows there are 91.18 million shares.
The 14.88% of Aquestive Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 45.85% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.79 million on 2025-01-15, giving us a short ratio of 7.25. The data shows that as of 2025-01-15 short interest in Aquestive Therapeutics Inc (AQST) stood at 1547.9999999999998 of shares outstanding, with shares short rising to 9.65 million registered in 2024-12-13. Current price change has pushed the stock -15.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AQST stock continues to rise going into the next quarter.
